- Home
- CHRS vs SWKH Comparison
CHRS vs SWKH Comparison
Compare CHRS & SWKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- SWKH
- Stock Information
- Founded
- CHRS 2010
- SWKH 1996
- Country
- CHRS United States
- SWKH United States
- Employees
- CHRS N/A
- SWKH N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- SWKH Diversified Financial Services
- Sector
- CHRS Health Care
- SWKH Finance
- Exchange
- CHRS Nasdaq
- SWKH Nasdaq
- Market Cap
- CHRS 194.1M
- SWKH 175.5M
- IPO Year
- CHRS 2014
- SWKH 1999
- Fundamental
- Price
- CHRS $1.69
- SWKH $16.84
- Analyst Decision
- CHRS Strong Buy
- SWKH Strong Buy
- Analyst Count
- CHRS 4
- SWKH 1
- Target Price
- CHRS $4.51
- SWKH $18.00
- AVG Volume (30 Days)
- CHRS 1.4M
- SWKH 47.1K
- Earning Date
- CHRS 11-05-2025
- SWKH 11-13-2025
- Dividend Yield
- CHRS N/A
- SWKH N/A
- EPS Growth
- CHRS N/A
- SWKH 55.18
- EPS
- CHRS 1.55
- SWKH 1.41
- Revenue
- CHRS $272,209,000.00
- SWKH $37,409,000.00
- Revenue This Year
- CHRS N/A
- SWKH $52.93
- Revenue Next Year
- CHRS $109.48
- SWKH N/A
- P/E Ratio
- CHRS $3.27
- SWKH $11.80
- Revenue Growth
- CHRS 52.33
- SWKH 47.31
- 52 Week Low
- CHRS $0.66
- SWKH $12.00
- 52 Week High
- CHRS $2.43
- SWKH $17.90
- Technical
- Relative Strength Index (RSI)
- CHRS 62.59
- SWKH 74.89
- Support Level
- CHRS $1.63
- SWKH $14.21
- Resistance Level
- CHRS $1.89
- SWKH $14.77
- Average True Range (ATR)
- CHRS 0.12
- SWKH 0.35
- MACD
- CHRS 0.00
- SWKH 0.12
- Stochastic Oscillator
- CHRS 64.42
- SWKH 68.77
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About SWKH SWK Holdings Corporation
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.